Introduction {#sec1}
============

Glioma is the most aggressive neoplastic disease in the central nervous system, which accounts for 80% of malignant primary brain tumors [@bib1]. According to the histological features, glioma can be classified into World Health Organization (WHO) grade I--IV [@bib2]. Recent advances showed that up to 80% of WHO II/III astrocytoma, oligodendroglioma, and secondary glioblastoma carry mutations in isocitrate dehydrogenase 1 and 2 (*IDH1/2*) [@bib3]. The identification of *IDH* mutations in glioma revealed a novel disease cluster that share distinctive cancer biology, metabolism signature, and therapeutic vulnerability [@bib3], [@bib4], [@bib5]. Although several pioneered studies reported that patients with *IDH*^*Mut*^ are commonly associated with prolonged overall survival (OS) with better chemosensitivities in comparison with *IDH* wild-type (*IDH*^*WT*^) glioma patients, effective cure for this glioma molecular subtype remains limited [@bib3], [@bib6], [@bib7].

Bone morphogenetic proteins (BMPs) are a group of growth factors that originally discovered by their involvement in the formation of bone and cartilage [@bib8]. BMPs are members of the transforming growth factor beta (TGF-β) family and recognize type I and II dual kinase receptors [@bib9]. Type I BMP receptors (BMPRs) consist of activin receptor--like kinase (ALK)-1, -2, -3 (BMPRIA) and -6 (BMPRIB). Type II BMPR includes BMP type II receptor (BMPRII), activin type II receptor (ActRII), and ActRIIB [@bib10]. The activated BMPRI initiates the intracellular signaling by phosphorylating the receptor-regulatory Smad1/5, which interacts with the common mediator Smad4 and translocates into nucleus [@bib10]. Besides their function in bone development, BMPs are recently identified participating key signaling pathways in cancer biology, such as cell proliferation, differentiation, and motility [@bib11]. BMP4 has been reported to be overexpressed in melanoma, colorectal cancer, and hepatocellular carcinoma and promotes the tumor invasion and metastasis [@bib12], [@bib13], [@bib14]. However, little is known about the expression and function of BMP4 in *IDH1*^*Mut*^ gliomas.

In the present study, we investigated the BMP4 expression in low-grade glioma (LGG). We identified a significant differential expression of BMP4 between *IDH1*^*WT*^ and *IDH1*^*Mut*^ cases. Further, we investigated the role of BMP4 on tumor aggressiveness in *IDH1*^*Mut*^ gliomas through patient-derived brain tumor--initiating cells (BTIC). Moreover, we demonstrate the cross-link between BMP/Smad signaling and canonical Wnt/β-catenin pathway. As a further validation, we evaluated the therapeutic effect of BMP4 blockade in preclinical xenograft model.

Materials and Methods {#sec2}
=====================

Cell Culture and Reagents {#sec2.1}
-------------------------

Glioma-initiating cells, GSC827, and GSC923 cell lines were derived from patients\' glioblastoma samples following the protocol of National Cancer Institute Institutional Review Board (NCI 02C-0140). *IDH1* R132H mutant TS603 cell line was kindly gifted from Dr. Timothy A. Chan\'s lab in Memorial Sloan Kettering Cancer Center. GSC827, GSC923, and TS603 were cultured in Neurobasal (Invitrogen) supplemented with N2, B27, EGF (20 ng/ml), bFGF (20 ng/ml), and 1% antibiotics (100 U/ml penicillin and 10 μg/ml streptomycin) as described before [@bib15]. These GSCs were monolayer cultured following the protocol as described before [@bib16]. To activate the BMP-Smads signaling, cells were treated with BMP4 (50 ng/ml, Thermo Fisher) for 30 min. To block the effect of BMP4, BMPR1A inhibitor LDN-193189 (200 nM, Sigma Aldrich) or BMP4 neutralizing antibody (NA, 8 μg/ml, R&D MAB757) was used to treat the cells.

Human Glioma Specimens {#sec2.2}
----------------------

Forty-six human glioma specimens were from Department of Neurosurgery, Beijing Tiantan Hospital affiliated to Capital Medical University and collected by Prof. Fusheng Liu\'s laboratory during 2015--2017 in Beijing Neurosurgical Institute ([Supplementary Table 1](#appsec1){ref-type="sec"}). Three experienced neuropathologists confirmed the histological diagnoses. The sample collection was approved by the Institutional Review Board of Beijing Tiantan Hospital affiliated to Capital Medical University.

Establishment of Intracranial *IDH1*^*Mut*^ Tumor Models {#sec2.3}
--------------------------------------------------------

Following the protocols as described before, six-week-old BALB/c-nu mice were injected with 5 × 10^5^ TS603 cells localizing to the caudate nucleus of mice brain [@bib17]. One week after injection, mice were randomly divided into two groups. The treatment group mice (LDN, *n* = 9) were intraperitoneally injected with LDN-193189 (3 mg/kg, MedChem Express) every day, and the control group mice (Ctrl, *n* = 9) were injected with DMSO. Animal studies were carried out in accordance with the NIH Guide for the Care and Use of Laboratory Animals.

RNA-Sequencing and Analysis {#sec2.4}
---------------------------

TS603 cells were treated with DMSO, BMP4 (50 ng/ml), LDN (200 nM), and BMP4 plus LDN for 3 days, respectively. Each treatment was prepared in triplicate. Total RNAs were extracted using PureLink RNA mini kit (Thermo Fisher), and the quality was assessed using RNA600 Pico LabChip kit with bioanalyzer (Agilent Technologies). The sequencing procedure was following the protocols as described before [@bib18]. Data were further analyzed using Ingenuity Pathway Analysis (Qiagen).

Statistical Analysis {#sec2.5}
--------------------

Statistical analysis was performed using GraphPad Prism 7. Student\'s *t*-test was used to analyze the significance of two group results. OS time of the mice was compared using log-rank method. All values are expressed as the mean ± SEM. *P* \< 0.05 was considered statistically significant. \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001.

Results {#sec3}
=======

Prompted Expression of BMP4 in *IDH1*^*Mut*^ Gliomas {#sec3.1}
----------------------------------------------------

To investigate the differential expressed genes between *IDH1*^*WT*^ and *IDH1*^*Mut*^ gliomas, we compared the transcriptome profile from 431 cases of *IDH1*^*Mut*^ gliomas and 96 cases of *IDH1*^*WT*^ gliomas based on the TCGA LGG database. We found out that *BMP4* expression is elevated by 72.5% in *IDH1*^*Mut*^ gliomas comparing with their wild-type counterparts ([Figure 1](#fig1){ref-type="fig"}A). The upregulation of BMP4 was further validated in 43 glioma specimens through immunohistochemistry assay (*IDH1*^*WT*^ = 13 cases; *IDH1*^*Mut*^ = 30 cases). We showed that BMP4 locates in the cytoplasm of glioma cells, which were elevated by 22.8% in *IDH1*^*Mut*^ glioma specimens ([Figure 1](#fig1){ref-type="fig"}B). To better understand the expression of BMP4 in *IDH1*^*Mut*^ glioma, we quantified the expression of *BMP4* in three human BTIC lines (*IDH1*^*WT*^: GSC827, GSC923; *IDH1*^*Mut*^: TS603). We found that mRNA levels of *BMP4* were elevated by up to 19.1 folds in *IDH1*^*Mut*^ TS603 cells ([Figure 1](#fig1){ref-type="fig"}C).Figure 1**BMP4 is overexpressed in*IDH1***^***Mut***^**human gliomas and cell lines.** (A) In TCGA database, *BMP4* is significantly increased in *IDH1*^*Mut*^ human gliomas than in *IDH1*^*WT*^ gliomas. (B) IHC staining of BMP4 in *IDH1*^*WT*^ and *IDH1*^*Mut*^ human gliomas. BMP4 expressed in cytoplasm. Scale bar: 50 μm. BMP4 was highly expressed in *IDH1*^*Mut*^ human gliomas. (C) In three GICs, BMP4 mRNA levels were higher in TS603 cells (*IDH1*^*Mut*^) than those in GSC827 and GSC923 cells (*IDH1*^*WT*^). (D) In cell medium supernatant, TS603 cells secreted significantly higher BMP4 levels than GSC827 and GSC923 cells. (E) BMP4 expression was detected in three GICs using western blot. BMP4 level was higher in TS603 cells. (F) In three GICs, the mRNA expression of *BMPRIA* was significantly upregulated in TS603 cells than in GSC827 and GSC923 cells. (G) The expression of BMPRIA was determined increased in TS603 cells than in GSC827 and GSC923 cells. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\*\**P* \< 0.0001.Figure 1

Several pioneered studies showed that cancer-associated BMP4 is secreted into tumor microenvironment, which therefore influences the progression of malignancy [@bib12], [@bib19]. To better illustrate the impact of BMP4 in the microenvironment of *IDH1*^*Mut*^ cells, we quantified the levels of BMP4 in cell culture media from BTIC by ELISA. Consistent with the BMP4 expression test, we found the BMP4 secretion was upregulated by 9.1-folds in *IDH1*^*Mut*^ TS603, compared with GSC827 or GSC923 ([Figure 1](#fig1){ref-type="fig"}D). As a further validation, we collected and concentrated the tissue culture media, and we found through western blotting that the secretion of BMP4 was higher in TS603 ([Figure 1](#fig1){ref-type="fig"}E). We also tested the expression level of BMP4 receptors in BTIC. We also investigated the expression of BMP4 and BMPR1A in these cell lines through immunoblotting ([Figure 1](#fig1){ref-type="fig"}F and G). These results showed that BMP4 is selectively upregulated in *IDH1*^*Mut*^ glioma cells comparing with *IDH1*^*WT*^ glioma cells, suggesting novel BMP signaling in *IDH1*^*Mut*^ glioma cells.

BMP4 Signaling Enhances Tumor Aggressiveness in *IDH1*^*Mut*^ Gliomas {#sec3.2}
---------------------------------------------------------------------

BMP4 has been shown to promote tumor migration and invasion in several types of human malignancies, mainly through its concomitant Smad1/5/8 signaling [@bib13], [@bib20], [@bib21]. To better understand the role of BMP4 in *IDH1*^*Mut*^ cells, we firstly analyzed the tumor migration rate in BTIC through wound healing assay. We applied LDN-193189 (LDN), a selective inhibitor for BMP type I receptor ALK2 and ALK3, to block BMP4/Smad signaling. We showed that the presence of BMP4 significantly enhanced cellular migration of TS603 cells, whereas the impact of BMP4 was abolished with LDN treatment ([Figure 2](#fig2){ref-type="fig"}A, mean wound width, DMSO = 534.2 ± 9.507 μm, BMP4 = 340.7 ± 24.36 μm, BMP4 + LDN = 535.8 ± 10.5 μm). The increased cellular motility was confirmed by transwell invasion assay. BMP4 increased cellular invasion 2.35 folds for TS603 cells, which was also abolished by LDN treatment ([Figure 2](#fig2){ref-type="fig"}B, invaded cell count, DMSO = 74 ± 4, BMP4 = 174 ± 7, BMP4 + LDN = 40 ± 1). As a further validation, we performed three-dimensional tumor spheroids invasion assay to better understand the alteration in glioma invasiveness. Consistently, we found that the presence of BMP4 resulted in aggressive invasion of TS603 cells. The cellular invasion was elevated by 70%, whereas LDN blocked TS603 cells penetration into the extracellular matrix ([Figure 2](#fig2){ref-type="fig"}C, area fold change T72h/T0h, DMSO = 22.38 ± 1.266, BMP4 = 38.08 ± 2.253, BMP4 + LDN = 18.01 ± 0.801). To further validate whether BMP4 enhances cellular invasiveness through its receptors, we established TS603 cells that stably express small hairpin RNAs targeting BMPR1A expression ([Supplementary Figure A](#appsec1){ref-type="sec"} and [B](#appsec1){ref-type="sec"}). Transwell invasion assay showed that the numbers of invaded cells were significantly decreased in cells with BMPR1A shRNA ([Figure 2](#fig2){ref-type="fig"}D). Similarly, three-dimensional tumor spheroids assay also showed the invaded areas of the BMPRIA knockdown cells were significantly decreased ([Figure 2](#fig2){ref-type="fig"}E, area fold change ratio T72h/T0h, shCtrl: 19.79 ± 0.9067, shRNA1: 5.429 ± 0.4193, shRNA2: 5.355 ± 0.4895). Moreover, the effect of BMP4 on cellular invasion was attenuated in BMPRIA knockdown cells ([Figure 2](#fig2){ref-type="fig"}F, area fold change, shCtrl: 32.41 ± 3.686, shRNA1: 13.71 ± 0.6709, shRNA2: 15.5 ± 0.758). These findings suggest that BMP4 potentiates aggressive phenotype for *IDH1*^*Mut*^ glioma cells, whereas BMPR blockade successfully prohibited cancer cells from infiltrating into adjacent extracellular matrix.Figure 2**BMP4 signaling enhances tumor aggressiveness in*IDH1***^***Mut***^**gliomas.** (A) Wound healing assay showed BMP4 treatment promoted the migration ability of TS603 cell. LDN blocked the effect of BMP4. Scale bar: 500 μm. (B) Transwell invasion assay showed that BMP4 treatment increased the invasive ability of TS603 cells. LDN blocked the effect of BMP4. Scale bar: 100 μm. (C) Three-dimensional tumor spheroids invasion assay showed that BMP4 treatment increased the invasive ability of TS603 cells. LDN blocked the effect of BMP4. Scale bar: 500 μm. (D) After BMPRIA was knocked down using shRNAs, the ability of invasion was significantly decreased in transwell invasive assay. Scale bar: 100 μm. (E--F) Knockdown of BMPRIA in TS603 cells decreased the ability of invasion in 3D tumor spheroids invasion assay; BMP4 could no longer promote the invasiveness in shRNAs cells. Scale bar: 500 μm. \*\**P* \< 0.01; \*\*\**P* \< 0.001.Figure 2

BMP4-Smad1 Signaling is Activated in an Autocrine Pattern {#sec3.3}
---------------------------------------------------------

To investigate how BMP4 alters the biology in glioma cells, we firstly determined the phosphorylation of Smad1, the concomitant downstream effector of BMPR signaling. Western blot showed Smad1 was phosphorylated under BMP4 treatment in three BTIC cells ([Figure 3](#fig3){ref-type="fig"}A). The phosphorylated Smad1 (p-Smad1) expression in *IDH1*^*Mut*^ TS603 cells was more significant, which might be attributed to the higher levels of BMPRIA. Further, the phosphorylation of Smad1 in TS603 cells is abolished by LDN in a dose-dependent manner. The BMP4-induced p-Smad1 expression could be completely inhibited by 200 nM LDN ([Figure 3](#fig3){ref-type="fig"}B). Meanwhile, we found that BMP4 NA attenuated the BMP4-induced p-Smad1 expression in a dose-dependent manner ([Figure 3](#fig3){ref-type="fig"}C).Figure 3**BMP4-Smad1 signaling is activated in an autocrine pattern.** (A) p-Smad1 expression was detected to be increased under the treatment of BMP4 for 0.5 h and 1 h, respectively. It was more significant when TS603 cells were treated with BMP4 for 0.5 h. (B) LDN-193189 (LDN) inhibited the BMP4-induced Smad1/5/8 phosphorylation in a dose-dependent manner. We used 200 nM concentration of LDN for the following study. (C) BMP4-neutralizing antibody (NA) inhibited the BMP4-induced Smad1/5/8 phosphorylation in a dose-dependent manner. We use 4 μg/ml concentration of BMP4 NA for the following study. (D) TS603 cells were treated using cell medium supernatant (conditioned medium, CM) in combination with LDN for 30 min; CM induced Smad1/5/8 phosphorylation and LDN blocked the effect of CM on Smad1/5/8 phosphorylation. (E) BMP4 NA attenuated the effect of CM-induced Smad1/5/8 phosphorylation in TS603 cells. (F) BRE-luciferase reporter assay showed BMP4 as well as CM increased the activity of luciferase, and which could be blocked by LDN and NA. (G) Transwell invasion assay showed that CM enhanced the invasiveness of TS603 cells, which could be blocked by LDN and NA. Scale bar: 100 μm. (H) Three-dimensional tumor spheroids invasion assay also showed that CM enhanced the invasiveness of TS603 cells, which could be blocked by LDN and NA. Scale bar: 500 μm. \*\**P* \< 0.01.Figure 3

Considering the high secretion level of BMP4 from TS603 cells, it is likely that the secreted BMP4 impact cellular biology through autocrine manner. To test this hypothesis, we collected the conditional media (CM) from TS603 cells and tested whether it could activate BMP/smad1 signaling. We found that CM treatment of TS603 cells induced the expression of p-Smad1, which could be blocked by LDN treatment ([Figure 3](#fig3){ref-type="fig"}D). Moreover, BMP4 NA inhibited the CM-induced p-Smad1 expression ([Figure 3](#fig3){ref-type="fig"}E). As a further validation, we measured the activation of Smad1 transcriptional activity by an *Id1* promoter--derived BMP reporter element (BRE)--luciferase reporter assay [@bib22]. We found out that both of BMP4 and CM significantly increased the activity of BRE-luciferase, and both of conditions were blocked by LDN and BMP4 NA ([Figure 3](#fig3){ref-type="fig"}F). These results strongly suggest that TS603 cells activate Smad signaling through BMP4 and BMPR activation.

We further investigated whether BMP4 autocrine supports aggressive phenotype in *IDH1*^*Mut*^ TS603 cells. Transwell invasion assay showed that CM significantly increased the invaded cell numbers, whereas LDN and BMP4 NA treatment blocked the effect of CM ([Figure 3](#fig3){ref-type="fig"}G, invaded cell count, DMSO = 63 ± 2, CM = 96 ± 3, CM + LDN = 27 ± 1, CM + NA = 32 ± 2). Consistently, CM treatment also increased the cellular penetration into adjacent extracellular matrix, which was also reversible by LDN or NA treatments ([Figure 3](#fig3){ref-type="fig"}H, invasion area fold change ratio T72h/T0h, DMSO = 26.98 ± 1.718, CM = 36.19 ± 1.617, CM + LDN = 19.91 ± 0.7548, CM + NA = 22.43 ± 1.29). Together with these results, we demonstrated that the autocrine of BMP4 in *IDH1*^*Mut*^ glioma cells promotes tumor aggressiveness, and LDN blockade suppressed the autocrine cycle via inhibiting the BMPRs.

BMP4-Smad1 Signaling Prompts Wnt Pathway via FZD1 {#sec3.4}
-------------------------------------------------

To explore the potential downstream genes or pathways of BMP4-Smad1 signaling that may be related to tumor aggressiveness, RNA-sequencing was performed to compare the expression profile before and after BMP4 treatment in *IDH1*^*Mut*^ glioma cells. Bioinformatic analysis showed differentially expressed gene sets involved in the activation of BMP4 signaling ([Figure 4](#fig4){ref-type="fig"}A). Among most significantly altered gene sets, we identified Wnt/β-catenin pathway as highly expressed signaling on BMP4 treatment. Within this pathway, Frizzled receptors (FZDs), a family of G protein--coupled receptors, are critical to activate β-catenin. Through quantitative real-time PCR, we showed that the expression of *FZD1* continuously increased under the treatment of BMP4 ([Figure 4](#fig4){ref-type="fig"}B). Western blot assay confirmed that the expression of FZD1 started to increase after 3 days of BMP4 treatment ([Figure 4](#fig4){ref-type="fig"}C). To investigate how BMP signaling activates FZD1 expression, we performed ChIP-qPCR to analyze the Smad1-binding sequences in *IDH1*^*Mut*^ TS603 cells. We found that BMP4 treatment significantly increased the affinity of Smad1 to FZD1 promoter region by 11.9-fold, suggesting that FZD1 expression was mediated by Smad1-associated transcriptional activation ([Figure 4](#fig4){ref-type="fig"}D). In addition, LDN and NA treatment reduced FZD1 expression in the presence of either BMP4 or CM, suggesting that FZD1 upregulation correlates with BMP4 autocrine ([Figure 4](#fig4){ref-type="fig"}E and F).Figure 4**FZD1 connects BMP4-Smad1 signaling with Wnt pathway.** (A) Top 20 highly activated pathways were listed in comparison of BMP4 vs DMSO group and BMP4 vs BMP4+LDN group from RNA-sequencing results. (B) The mRNA expression of FZD1 was continuously increased under the treatment of BMP4 in a time-dependent manner. (C) Western blot showed that BMP4 treatment increased the expression of Id1 and FZD1. The expression of FZD1 started to increase at day 3. (D) TS603 cells were treated with BMP4 for 72 h. ChIP-qPCR revealed that BMP4-Smad1 signaling directly regulated the expression of *FZD1*. (E--F) BMP4 and CM treatment of TS603 for 24 h significantly upregulated the expression of *FZD1*. Both of LDN-193189 and BMP4 neutralizing antibody could block the effect of BMP4-induced *FZD1* expression. \*\**P* \< 0.01; \*\*\**P* \< 0.001.Figure 4

To further verify the crosstalk between BMP/Smad signaling and Wnt/β-catenin pathway, we measured the expressions of downstream genes of Wnt/β-catenin signaling, such as *c-Myc* and *Axin2*, by real-time PCR. We found BMP4 enhanced the transcriptional activation of both genes under Wnt3a induction ([Figure 5](#fig5){ref-type="fig"}A and B). Moreover, we established TS603 cells with stably expressed shRNA targeting *BMPR1A*. We found the in these cells, the impact of BMP4 to *c-Myc* and *Axin2* was abolished ([Figure 5](#fig5){ref-type="fig"}C and D). These results suggested BMP4 potentiates Wnt/β-catenin signaling, which requires the receptor such as BMPR1A. Consistently, Axin2-luciferase reporter assay also showed that BMP4 or CM treatment significantly increased the activity of Axin2-luciferase comparing with Wnt3a treated alone ([Figure 5](#fig5){ref-type="fig"}E and F).Figure 5**BMP4-Smad1 signaling promotes the activity of Wnt/β-catenin pathway via upregulating FZD1.** (A--B) *c-Myc and Axin2*, downstream of Wnt/β-catenin pathway, were significantly upregulated under the treatment of BMP4 for 72 h in combination with Wnt3a for 6 h. (C--D) After BMPRIA was knocked down, BMP4 in combination with Wnt3a treatment could no longer significantly induce the expression of *c-Myc* and *Axin2*. (E--F) Axin2-luciferase reporter assay showed that the activity of luciferase could be increased under the treatment of BMP4 or CM in combination with Wnt3a. \*\**P* \< 0.01; \*\*\**P* \< 0.001.Figure 5

LDN Inhibits Tumor Progression and Prolongs the Overall Survival of Mice with Intracranial *IDH1*^*Mut*^ Gliomas {#sec3.5}
----------------------------------------------------------------------------------------------------------------

Our above findings showed that LDN inhibits BMP4-Smad1 signaling and hence suppresses tumor aggressiveness *in vitro*. To clarify whether inhibition of BMPR blockade by LDN could be considered as potential therapeutic approach, we established intracranial *IDH1*^*Mut*^ glioma models using TS603 cells and evaluated the therapeutic effect of LDN. OS of the LDN-treated mice were significantly prolonged comparing with the control group ([Figure 6](#fig6){ref-type="fig"}A, median survival: DMSO group = 78 days, LDN group = 94 days). H&E staining of the two group mice brain, which were extracted from survival day 87 and day 88, showed that the midline of the brain obviously shifted toward the normal side in DMSO group ([Figure 6](#fig6){ref-type="fig"}B). IHC results showed that p-Smad1/5 expression and Id1 expression were significantly downregulated in the LDN-treated mice brains ([Figure 6](#fig6){ref-type="fig"}C). Besides, in LDN-treated mice brains, c-Myc and Axin2 expressions were also found to be decreased ([Figure 6](#fig6){ref-type="fig"}D). These results suggested that LDN could be an effective inhibitor for BMP4 signaling and hence suppress the tumor progression in *IDH1*^*Mut*^ gliomas.Figure 6**LDN prolongs the overall survival of mice with intracranial*IDH1***^***Mut***^**gliomas.** (A) LDN treatment significantly prolonged the overall survival of mice with intracranial *IDH1*^*Mut*^ gliomas. Log-rank test. (B) H&E staining of mice brains in DMSO (*n* = 9) and LDN (*n* = 9) groups. The medium survival (MS) of DMSO-treated mice was 78 days, and the MS of LDN-treated mice was 94 days. Scale bar: 2 mm. (C) IHC staining of p-Smad1/5 and Id1 in mice brains. p-Smad1/5 localized in nucleus and Id1 localized in both of cytoplasm and nucleus. Scale bar: 50 μm. The expression of p-Smad1/5 and Id1 was decreased under the treatment of LDN. (D) IHC staining of c-Myc and Axin2 in mice brains. c-Myc localized in nucleus and Axin2 localized in cytoplasm. Scale bar: 50 μm. The expression of c-Myc and Axin2 was inhibited under the treatment of LDN. \*\**P* \< 0.01.Figure 6

Discussion {#sec4}
==========

In the present study, we found through bioinformatic approaches that BMP4 is upregulated in *IDH1*^*Mut*^ gliomas in comparison with *IDH1*^*WT*^ gliomas. We demonstrated that BMP4 is overexpressed in patient-derived *IDH1*^*Mut*^ glioma specimens and *IDH1*^*Mut*^ glioma cells. The BMP4 autocrine loop promotes tumor aggressiveness evidenced by prompted cellular migration and invasion. LDN-193189, a selective inhibitor for BMPRs, blocks the effect of BMP4 and hence inhibits the tumor aggressiveness and prolongs the OS of xenograft mice. Moreover, we discovered that BMP4-Smad1 signaling promotes the activity of Wnt/β-catenin pathway via upregulating the expression of FZD1 ([Supplementary Figure A](#appsec1){ref-type="sec"}). Our findings highlight a critical role of BMP4 in *IDH1*^*Mut*^ glioma aggressiveness and reveal a potential therapeutic approach for *IDH1*^*Mut*^ glioma patients.

The Expression of BMP4 in Human Gliomas {#sec4.1}
---------------------------------------

In human gliomas, several pioneered studies have investigated through two glioma data sets (CGGA and GSE16011 data sets) and showed that BMP4 is significantly upregulated in *IDH1*^*Mut*^ gliomas other than *IDH1*^*WT*^ gliomas [@bib23]. Our study confirmed this finding through analyzing TCGA database. We found that BMP4 expression is significantly upregulated in *IDH1*^*Mut*^ gliomas as compared with *IDH*^*WT*^ counterparts. This result was confirmed using IHC staining of BMP4 in 46 human glioma specimens. In BTICs, the significantly higher levels of BMP4 expression were also recorded in *IDH1*^*Mut*^ cells than in *IDH1*^*WT*^ cells. Importantly, the secretion level of BMP4 in *IDH1*^*Mut*^ cells was found to be much higher than *IDH1*^*WT*^ cells, suggesting the tumor cells could be capable to impact microenvironment through BMP4 release ([Figure 1](#fig1){ref-type="fig"}). These results showed that BMP4 is upregulated in *IDH1*^*Mut*^ glioma specimens and cells. Considering the high incidence of *IDH* mutation in LGGs, it is crucial to understand the underlying biology signature with BMP signaling.

The Role of BMP4 in *IDH1*^*Mut*^ Gliomas {#sec4.2}
-----------------------------------------

BMP4 has been found exhibiting critical biological functions that are related to cell proliferation, differentiation, apoptosis, migration, invasion, and epithelial--mesenchymal transition (EMT) [@bib24]. In the several types of tumors, BMP4 showed inhibitory effect on cancer cell growth, including myeloma, breast, gastric, and pancreatic cancers [@bib25], [@bib26], [@bib27], [@bib28]. BMP-Smad signaling have been demonstrated to promote reprogramming to pluripotency by inhibiting p16/Ink4a [@bib29].However, in brain tumors, BMP4 shows different biological on tumor cells of different histological and molecular subtypes. BMP4 increases the cell growth of meningioma, whereas inhibits the proliferation of GBM cells [@bib30], [@bib31]. Similarly, in our patient-derived cell models, we did not observe obvious effect on cell proliferation by BMP4 treatment ([Supplementary Figure D](#appsec1){ref-type="sec"} and [E](#appsec1){ref-type="sec"}). On the other hand, BMP4 has been reported remarkably to activate cellular migration and invasion in several types of malignancies such as colorectal cancer cells, ovarian cancers, hepatocellular carcinoma, and melanoma and thus promote the aggressiveness of tumor cells [@bib13], [@bib31], [@bib32], [@bib33], [@bib34]. However, only few studies have reported the role of BMP4 on tumor aggressiveness in gliomas, especially in *IDH1*^*Mut*^ gliomas. In the present study, we demonstrated that BMP4 promotes the cell migration and invasion in *IDH1*^*Mut*^ glioma cells ([Figure 2](#fig2){ref-type="fig"}). In addition, when BMPRIA was knocked down using shRNAs, the invasiveness of *IDH1*^*Mut*^ gliomas cells were significantly inhibited. These results demonstrated that the overexpression of BMP4 in *IDH1*^*Mut*^ gliomas is contributing effects on tumor aggressiveness.

Autocrine BMP4 Signaling in *IDH1*^*Mut*^ Gliomas {#sec4.3}
-------------------------------------------------

Several studies have reported that the BMP4 signaling tends to promote tumor growth, pathogenesis, and aggressiveness through autocrine manner [@bib12], [@bib33], [@bib35], [@bib36]. For example, in human ovarian cancer cells, autocrine BMP4 signaling contributes to cancer pathogenesis via regulating *ID3* protooncogene expression [@bib36]. In colorectal cancer, inhibition of autocrine BMP4 signaling induces tumor apoptosis through attenuation MAPK activity [@bib12]. In the present study, we found that the secretion of BMP4 in TS603 cells are significantly higher than in GSC827 and GSC923 cells ([Figure 1](#fig1){ref-type="fig"}D), which indicates that BMP4 autocrine loop may play a role in the biology of *IDH1*^*Mut*^ glioma cells. Furthermore, we showed that tumor-derived BMP4 activated to the phosphorylation of Smad1 and aggressive phenotypes, which can be blocked by LDN or BMP4 NA ([Figure 3](#fig3){ref-type="fig"}). These results suggested that the BMP4 autocrine loop from *IDH1*^*Mut*^ glioma cells enhances the tumor aggressiveness.

BMP4 Signaling Prompts with Wnt/β-Catenin Pathway {#sec4.4}
-------------------------------------------------

The link between BMP4 and Wnt signaling has been shown in several different types of tumors [@bib24]. Wnt3a activation was discovered to increase BMP4 expression in C4--2B and PC3 prostate cancer cells [@bib37]. β-Catenin was found to specifically promote BMP4 expression and secretion in HCT116 cells [@bib38]. In present study, we performed RNA-sequencing to investigate the downstream effector of BMP4 signaling. Surprisingly, we found that FZD1, which is one of the receptors in Wnt/β-catenin pathway, was upregulated under the treatment of BMP4. Moreover, ChIP-qPCR confirmed that BMP4-induced Smad1 directly binds to the promoter region of *FZD1*, suggesting the crosstalk is through Smad1-associated gene transcription ([Figure 4](#fig4){ref-type="fig"}). This is in accordance with a previous study showing that FZD1 is the downstream of BMP-Smad signaling [@bib39]. Moreover, we also demonstrated that BMP4-induced upregulation of FZD1 promotes the activity of Wnt/β-catenin pathway and hence increases the expression of the downstream genes, such as c-Myc and Axin2 ([Figure 5](#fig5){ref-type="fig"}). These results suggested that BMP4-Smad1 signaling promotes the activity of Wnt/β-catenin pathway via upregulating FZD1.

BMP Signaling Inhibitor LDN-193189 as a Potential Therapeutic for *IDH1*^*Mut*^ Glioma {#sec4.5}
--------------------------------------------------------------------------------------

LDN is a cell-permeable, highly effective, and selective inhibitor for BMP type I receptors ALK2 and ALK3. It inhibits BMP4-mediated Smad1, Smad5, and Smad8 phosphorylation and exerts substantially weaker effects on activin and TGF-β type I receptors and hence increases the selectivity for BMP signaling [@bib40]. Previous studies reported that LDN suppresses tumor initiating capacity, increases tumor latency, and inhibits EMT and tumor progression or metastasis in various kinds of cancers [@bib41], [@bib42], [@bib43]. Augeri et al. showed that inhibition of BMP downregulates the expression of XIAP and TAK1 leading to tumor cell death [@bib44]. Our results revealed that LDN showed remarkable inhibitory effects on tumor migration and invasion in *IDH1*^*Mut*^ glioma cells ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}) and prolongs OS of mice bearing intracranial *IDH1*^*Mut*^ xenografts ([Figure 6](#fig6){ref-type="fig"}). We also demonstrated that intraperitoneally injection of LDN suppresses the activity of BMP4-Smad1 signaling and hence the Wnt/β-catenin pathway *in vivo*. These results suggest that LDN may be an effective molecule for suppressing tumor aggressiveness in *IDH1*^*Mut*^ gliomas.

In summary, our results demonstrated that BMP4 is overexpressed in *IDH1*^*Mut*^ gliomas and enhances tumor migration and invasion in an autocrine pattern. BMP4 signaling promotes the activity of Wnt/β-catenin pathway via upregulating FZD1. Moreover, LDN, a selective inhibitor for BMP4 signaling, prevents the tumor progression and prolongs the survival of mice with *IDH1*^*Mut*^ xenografts.
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